 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research.

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
A Blueprint For Clinical Research: Standard Operating Procedures
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
Multi-Institutional Facilitated IRB Review Philip A. Cola, MA Vice President, Research and Technology University Hospitals Case Medical Center Third Annual.
Submission to Approval What happens to my protocol once I submit it to the HIC office.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.
CRC Protocol Documents Protocol Submissions Amendments Publications Study Closure.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
National Cancer Institute (NCI) Central Institutional Review Board (CIRB) Research Studies UCSF HRPP Submission Process Overview Tuesday, December.
Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.
IRB Basics Helen Panageas New York University School of Medicine Institutional Review Board Portion of slides courtesy of Suzanne M. Smith, University.
Telemedicine Credentialing and Privileging October 16, 2014.
I T ’ S J UST A L ITTLE C HANGE ; O H AND I T ’ S T IME TO R ENEW ! H OW TO SUBMIT AMENDMENTS AND RENEWALS Human Investigation Committee Human Research.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Institutional Review Board (IRB) Human Subject Research Office (HSRO) University of Miami and Affiliated Institutions.
NANCY ABBOTT CANR GRANTS DEVELOPMENT OFFICER [GDO] CANR Sponsored Project Proposal Process.
Office of Sponsored Programs November  Focus on What is Important  Proposal Structure  Proposal Development Process  Proposal Review.
Working with Quorum Allina Health Megan Simpson, CIP Senior Study Manager Allina Account Manager.
The Office of Research Program Development. The Office of Research Program Development (RPD) was established in 1993 to facilitate and foster multidisciplinary.
Research and Development Protocol Submission and Continuing Review Processes Kimberly Summers, PharmD Assistant Chief for Clinical Research South Texas.
The proper protocol for grant approval at LCSC GRANT-WRITING 101: INTERNAL PROCEDURES.
Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
New IRB Guideline Changes and Converting to eIRB - Suggestions for Maintaining Compliance. Ramesh Ghodgaonkar, BPHARM, MSITS, MSB, MBA Betsy Johnson, BA.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
Investigational New Drug Application (IND)
Common Audit Findings UTHSC Institutional Review Board (IRB)
Got the Grant What’s next??????????? Joy R. Knipple Team Leader, National Institute of Mental Health July 26, 2006.
Deciphering the Continuing Review Form Research Compliance Administration Training Presentation Wednesday, August 15, 2007 Presenter:Heather Kemp, MBA.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
CTEP Protocol and Information Office (PIO) Overview.
Tips on Routing and Contracts: An Intro for the Campus Research Coordinator Michelle Artmeier Director of Award Services Ron.
H I P A A T R A I N I N G Self Directed Module 7 Research Disclosures For Data Custodians START Click to begin…
SPS policy – Information Presentation Presentation to ROS June 16, 2004.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
CTN Study Submission & Review Process Update June 2 nd, 2015.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Leslie Howes, MPH, CIP Alyssa Speier, MS, CIP September 24, 2014 Investigator Manual: ra/investigator-manual/
IRB  Keep IRB information for each protocol in a separate folder or separate by dividers  All IRB approvals for treatment and stand alone companions.
CTEP Plans: Consensus Reviews & Templates Andrea Denicoff, MS, RN, ANP Clinical Investigations Branch CTEP, DCTD OEWG Kick-Off Meeting March 23, 2010.
ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.
Research Orientation to SCCA. What is the SCCA? The SCCA brings together the outstanding adult and pediatric oncology patient care services of three world-
CTRP User Call May 7, 2014 Gene Kraus CTRP Program Director.
Ver. 02/13/  Registration  New Studies  Continuing Reviews  Amendments  Reportable Events  Tips & Tricks  Questions 2.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Commission on Teacher Credentialing Ensuring Educator Excellence 1 Program Assessment Technical Assistance Meetings December 2009.
Fully accredited since 2006 Tom Conquergood, CIP Working with Quorum October 13, 2015 Thomas Jefferson University.
Welcome New IRB Member! This brief presentation covers: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
Page  ASME 2013 Standards and Certification Training Module B – Process B7. The Appeals Process.
NCI Clinical Trials Reporting Program CTRP User Meeting June 6, 2012 Gene Kraus CTRP Program Director.
ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.
6/9/2016 Agenda Procedure Training Lori McWilliams, CMC Village Clerk.
1 MARCH 2012 Regulatory Documents & the CTSU.
Opening An ETCTN Study at Your Site August Scope of this Presentation  This presentation applies to all sites which will be participating on.
Lifespan 1 Submission Process to the IRB part 2 Revisions to Protocol.
ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
COCE Institutional Review Board Academic Spotlight
MAINTAINING THE INVESTIGATOR’S SITE FILE
Clinicaltrials.gov Update
SUNY Pre Award and Compliance Systems Institutional Review Board (IRB)
Clinical Trial Development: NRG Processes and NCI Requirements
Clinical Trial Development: NRG Processes and NCI Requirements
Presentation transcript:

 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research on anti-cancer agent development  Organized into the Office of the Director, one Center, and six Divisions, each specializing in a different aspect of cancer research. 2

3

 The Protocol and Information Office was created to serve as the central hub of information processing for maintaining the official files of all protocols in which CTEP is involved. 4

 The PIO manages the entire protocol process. Protocol processing begins with the submission of a clinical study via either a Letter of Intent (LOI) or a Concept Review. The PIO follows each protocol through the steps of the review and approval processes. Amendment changes, monitoring, correspondence, and receipt of a final published report are additional tasks of the PIO throughout the lifecycle of the protocol. 5

 The primary mission of the PIO is to facilitate the development of quality clinical trials in the most efficient and expeditious manner possible and to relieve the administrative burden related to clinical trial development and management on CTEP staff and the extramural community. 6

 In order to assist in meeting the mission of CTEP, the following services are in full operation:  Document management  Keywords and milestones abstraction into the Enterprise System (CTEP’s database for all protocol related activities)  Education of all concerned parties regarding NCI programs, policies, and objectives related to clinical trial development and management  Training of PIO staff, extramural investigators, and CTEP reviewers  Administrative support, including document tracking, scientific writing, and technological discovery to streamline the protocol development process 7

 Support CTEP committees by organizing and preparing protocols for weekly Protocol Review Committee (PRC) and Investigational Drug Committee (IDB) meeting in which drug development strategies and related issues are discussed.  Documentation accuracy and quality assurance (QA) to ensure that all official documentation is correctly noted and filed in database.  Correspondence between CTEP and its investigators (protocol approval, Safety/Action Letters, etc.)  Responding to questions from clinical sites 8

 The PIO staff is comprised of:  3 government staff:  Head of PIO  Deputy Head of PIO  Technical Assistant  10 contract staff:  Program Manager  Deputy Program Manager  LOI/Concept Coordinator  6 Protocol Specialists  1 Support Staff 9

 Letter of Intent (LOI):  An investigator’s declaration of interest in conducting a Phase I or Phase II trial with an investigational drug  LOIs should be submitted for all Phase I or Phase II trials that will utilize Division of Cancer Treatment and Diagnosis, CTEP supplied IND agents  Once an LOI is approved by CTEP, a protocol submission is expected within 30 days  LOI submission form (MS Word ) can be found on the CTEP Web site at: 10

 Concept:  Disease oriented Phase III proposals that are not fully developed research protocols  Once a Concept is approved by CTEP, the Concept Coordinator guides the investigator to the timely 30 day delivery of a protocol submission.  Concept submission form (MS Word) can be found on the CTEP Web site at: 11

 New CTEP Protocol:  The detailed written plans of a clinical trial or experiment. A protocol must be approved by CTEP and the local IRB before any patients are enrolled (accrued/treated).  Templates for all Phases of Clinical Trials are available on the Web site at:  Initial submission of a protocol must include the following:  Cover letter from the Protocol Chair or PI stating the intent of the new submission  Protocol Submission Worksheet (PSW): current version available on the web site at  One electronic paginated, legible protocol, including all appendices, if applicable 12

 Patient Informed Consent (guidelines available on the web site at: ngInformedConsent)  The Protocol document should contain the following:  Title page including the title of the study, version date, local protocol number (if applicable), PI/Protocol Chair including name, address, phone number, fax number, and address and for DCTD-supplied IND drugs, a listing of each drug by name and NSC number  Table of Contents (titles should match the body of the protocol)  Body of Protocol (objectives, background, eligibility, etc.)  Appendices (if applicable)  Model Patient Informed Consent (if applicable) 13

 Revision:  Any protocol changes which occur before CTEP approval.  All revised protocols submissions should include:  Cover letter from the Protocol Chair or PI identify by page AND section each change made to a protocol document. All responses to the Consensus Review/Follow-up Review or additional changes shall be described in a point-by-point format (i.e. Page 3, section 1.2, replace ‘xyz’ and insert ‘abc’). The original change request letter shall be attached.  A revised un-marked (without handwritten notes or highlights) copy of the protocol document INCLUDING all protocol attachments listed in the table of contents regardless of whether any changes occurred to these sections. 14

 Informed Consent regardless of whether any changes occurred to this document.  Protocol title page must include a Version Date that reflects the time-point of the most recent change to the document.  OPTIONAL – In addition to the above, you may include a revised copy of the protocol with all changes specified in the Revision cover letter highlighted throughout the document utilizing a word-processing program. 15

16 1. New Protocol Arrives, is Checked by PIO and Reviewed at PRC 5. Amendments are Received, Reviewed and Approved/ Disapproved 3. Protocol is Sent to FDA and Distributed to PDQ and Other Contractors 2.PRC Reviewers Interact with the PI Through Consensus Review / Follow-Up Reviews Until Protocol is Approved (Revision Process) Administrative Life of a Protocol at CTEP 6.Status Updates: Closures and Complete 4. Protocol is Activated By PI

17 Complete ? PIO contacts PI requesting missing or corrected pieces of the protocol. Protocol processing is stopped until document is correct and complete YESYES Acknowledgement letter sent to PI and MAILTO Abstract data in database including CTEP Reviewers Copies distributed to Reviewers on Friday Schedule for Protocol Review Committee Meeting (PRC) in 2 weeks PRC (every Thursday) Completeness Check PSW submitted with correct targeted accrual table (ph 2 and 3 studies) Title page contains version date, PI & contact info, other participants Table of Contents – sections and page numbers match protocol and includes allappendices All pages numbered sequential- no blank pages Consent form present and paginated correctly All Appendices present and paginated correctly Reviewed for Completeness NO New Protocol Received

18 PRC Approved or Approved with Recommendations or Disapproved Issues ? Letter to PI NO YESYES Pending

19 Pending Consensus/ Follow-up Review sent to PI outlining changes that must be made prior to approval as well as recommendations which may or may not be made Site has 30 days to respond to CR and 2 weeks to respond to follow-up review PIO contacts PI requesting missing or corrected pieces of the protocol. Protocol processing is stopped until document is correct and complete Complete? Abstract data into Pats including the CTEP reviewers Quality Check Routed to reviewers Approved or Approved with Recommendations or Issues? Disapproved Yes NONO No Letter to PI Cover letter addresses point by point the CR or Follow-up review including page and section #s as well as what was changed Title page of protocol contains version date Table of Contents Section numbers and titles match the protocol Page numbers match Includes all appendices All pages of the protocol are numbered sequentially and there are no blank pages Consent form Submitted and paginated correctly Appendices submitted and paginated Response sent electronically to PIO This becomes revision for CTEP Reviewed for Completeness Completeness checks Yes

 Amendment:  Any protocol changes which occur after CTEP approval.  Amendment guidelines can be found on the CTEP Web site 20

 The following documentation MUST be included with every Amendment-request submission:  Cover letter from the Protocol Chair or PI identify by page AND section each change made to a protocol document. All changes shall be described in a point-by-point format (i.e. Page 3, section 1.2, replace ‘xyz’ and insert ‘abc’). When appropriate a brief justification for the change should be included.  A revised un-marked (without handwritten notes or highlights) copy of the protocol document regardless of whether any changes occurred to the protocol INCLUDING all protocol attachments listed in the table of contents.  Informed Consent regardless of which changes occurred to this document.  Protocol title page shall include a Version date that reflects the time- point of the most recent change to the document.  If the amendment is in response to a CTEP or FDA request for change the original change request letter shall be attached.  OPTIONAL – In addition to the above, you may include a revised copy of the protocol with all changes specified in the Amendment-request cover letter highlighted throughout the document utilizing a word- processing program. 21

22 Amendment Received in PIO PIO contacts PI requesting missing or corrected pieces of the protocol. Protocol processing is stopped until document is correct and complete NO YESYES Abstract data in database Routed to appropriate reviewers Approved To FDA if appropriate Letter to PI Reviewed for Completeness Completeness Check Change Memo complete with page #s, Sect #s, changes made “from” and “to” Title page contains version date, PI & contact info, other participants Table of Contents – sections and page numbers match protocol and includes allappendices All pages numbered sequential- no blank pages Consent form present and paginated correctly All Appendices present and paginated correctly Complete ?

 Status Notice/Protocol Status Update  These are notices received in the PIO stating the status of a protocol (active, closed to accrual, closed to accrual and treatment, administratively completed, completed, or publication citation).  Protocol Status Update form is available on the web site at:  IRB Approval  Each investigator must meet the requirement of the Federal regulations for human subjects assurances and informed consent and for IRB review and approval.  Evidence of IRB approval may be submitted to CTEP at any time in the review process. Each protocol must have documentation of IRB approval prior to CTEP approval. 23

 In order to better disseminate accurate and current information, the CTEP Web page is available to the public, investigators, and other Government officials as a resource:  ctep.cancer.gov  is the preferred method of communication with the PIO:   Include the NCI Protocol number (if any) in the subject line of the . 24